166 related articles for article (PubMed ID: 18510632)
1. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.
Margreiter R; Klempnauer J; Neuhaus P; Muehlbacher F; Boesmueller C; Calne RY
Am J Transplant; 2008 Jul; 8(7):1480-5. PubMed ID: 18510632
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
[TBL] [Abstract][Full Text] [Related]
3. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial.
Chan K; Taube D; Roufosse C; Cook T; Brookes P; Goodall D; Galliford J; Cairns T; Dorling A; Duncan N; Hakim N; Palmer A; Papalois V; Warrens AN; Willicombe M; McLean AG
Transplantation; 2011 Oct; 92(7):774-80. PubMed ID: 21836540
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial.
Bösmüller C; Ollinger R; Sieb M; Weissenbacher A; Schneeberger S; Pratschke J; Margreiter R
Ann Transplant; 2012 Dec; 17(4):45-51. PubMed ID: 23274323
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
Kirsch BM; Haidinger M; Zeyda M; Böhmig GA; Tombinsky J; Mühlbacher F; Watschinger B; Hörl WH; Säemann MD
Transpl Immunol; 2006 Nov; 16(3-4):254-7. PubMed ID: 17138063
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial.
Welberry Smith MP; Cherukuri A; Newstead CG; Lewington AJ; Ahmad N; Menon K; Pollard SG; Prasad P; Tibble S; Giddings E; Baker RJ
Transplantation; 2013 Dec; 96(12):1082-8. PubMed ID: 24056618
[TBL] [Abstract][Full Text] [Related]
8. The use of Campath-1H as induction therapy in renal transplantation: preliminary results.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roohipour R; Carreno MR; Roth D; Ruiz P; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2004 Aug; 78(3):426-33. PubMed ID: 15316372
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab induction in deceased donor kidney transplantation.
Huang E; Cho YW; Hayashi R; Bunnapradist S
Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Kupin W; Rosen A; Cordovilla T; Tueros L; Herrada E; Miller J
Clin Transplant; 2008; 22(2):200-10. PubMed ID: 18339140
[TBL] [Abstract][Full Text] [Related]
11. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation.
Uemura T; Ramprasad V; Matsushima K; Shike H; Valania T; Kwon O; Ghahramani N; Shah R; Farooq U; Khan A; Kadry Z
Transplantation; 2011 Sep; 92(6):678-85. PubMed ID: 21841541
[TBL] [Abstract][Full Text] [Related]
12. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.
Tan HP; Kaczorowski DJ; Basu A; Unruh M; McCauley J; Wu C; Donaldson J; Dvorchik I; Kayler L; Marcos A; Randhawa P; Smetanka C; Starzl TE; Shapiro R
Am J Transplant; 2006 Oct; 6(10):2409-17. PubMed ID: 16889606
[TBL] [Abstract][Full Text] [Related]
13. Campath-1H in renal transplantation: The University of Wisconsin experience.
Knechtle SJ; Fernandez LA; Pirsch JD; Becker BN; Chin LT; Becker YT; Odorico JS; D'alessandro AM; Sollinger HW
Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results.
Kaufman DB; Leventhal JR; Axelrod D; Gallon LG; Parker MA; Stuart FP
Am J Transplant; 2005 Oct; 5(10):2539-48. PubMed ID: 16162205
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation.
Shapiro R; Ellis D; Tan HP; Moritz ML; Basu A; Vats AN; Kayler LK; Erkan E; McFeaters CG; James G; Grosso MJ; Zeevi A; Gray EA; Marcos A; Starzl TE
Am J Transplant; 2007 Dec; 7(12):2736-8. PubMed ID: 17908272
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
Farney A; Sundberg A; Moore P; Hartmann E; Rogers J; Doares W; Jarrett A; Adams P; Stratta R
Clin Transplant; 2008; 22(1):41-9. PubMed ID: 18217904
[TBL] [Abstract][Full Text] [Related]
17. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy.
McCurry KR; Iacono A; Zeevi A; Yousem S; Girnita A; Husain S; Zaldonis D; Johnson B; Hattler BG; Starzl TE
J Thorac Cardiovasc Surg; 2005 Aug; 130(2):528-37. PubMed ID: 16077423
[TBL] [Abstract][Full Text] [Related]
18. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience.
Tan HP; Kaczorowski DJ; Basu A; Khan A; McCauley J; Marcos A; Fung JJ; Starzl TE; Shapiro R
Transplantation; 2004 Dec; 78(11):1683-8. PubMed ID: 15591960
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
[TBL] [Abstract][Full Text] [Related]
20. Early outcomes using alemtuzumab induction in lung transplantation.
van Loenhout KC; Groves SC; Galazka M; Sherman B; Britt E; Garcia J; Griffith B; Iacono A
Interact Cardiovasc Thorac Surg; 2010 Feb; 10(2):190-4. PubMed ID: 19939852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
